HU
HUMA.US Humacyte Inc
- Market cap
- USD 155M
- P/E
- -
- P/B
- 8.59x
- ROE
- -516.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is HUMA.US undervalued?
Graham numberThe Graham number of Humacyte Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Humacyte Inc fundamental analysis
No fundamental analysis for Humacyte Inc yet.
Humacyte Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Humacyte Inc
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to …
Full company profileHumacyte Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Humacyte Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 6.19M | 1.49M | 1.26M | 1.57M | 0.00 | 0.00 | 2.04M | 2.57M |
| Gross Profit | -69.4M | -52.6M | -60.1M | -6.69M | -76.6M | -7.19M | -15.0M | -3.69M |
| Operating Income | -85.7M | -64.6M | -81.2M | -84.6M | -100M | -114M | -107M | -106M |
| EBITDA | -78.9M | -56.2M | -13.9M | 2.45M | -96.5M | -132M | -22.2M | -77.7M |
| Net Income | -85.4M | -66.5M | -26.5M | -12.0M | -111M | -149M | -40.8M | -93.3M |
| EPS | -0.83 | -5.34 | -0.66 | -0.12 | -1.07 | -1.26 | -0.26 | -0.34 |
| Balance Sheet | ||||||||
| Total Assets | 169M | 107M | 287M | 204M | 128M | 138M | 116M | 126M |
| Total Liabilities | 36.5M | 36.0M | 164M | 87.4M | 115M | 191M | 113M | 108M |
| Shareholders' Equity | 132M | 70.7M | 122M | 117M | 13.5M | -52.7M | 3.11M | 18.1M |
| Cash & Short-term Investments | 93.7M | 39.9M | 226M | 152M | 80.4M | 44.9M | 50.5M | 64.5M |
| Total Debt | 28.7M | 28.9M | 51.2M | 50.1M | 57.5M | 16.5M | 64.8M | 65.9M |
| Cash Flow | ||||||||
| Operating Cash Flow | -71.8M | -55.6M | -81.2M | -71.1M | -73.3M | -98.1M | -105M | -82.9M |
| Capital Expenditure | 8.13M | 318K | 220K | 1.05M | 2.28M | 1.57M | 884K | 372K |
| Free Cash Flow | -79.9M | -55.9M | -81.4M | -72.2M | -75.6M | -99.7M | -106M | -83.2M |
| Ratios | ||||||||
| ROE | -64.6% | -94.1% | -21.7% | -10.2% | -817.8% | - | -1,313.4% | -516.4% |
| ROA | -50.6% | -62.4% | -9.2% | -5.9% | -86.4% | -107.9% | -35.1% | -74.3% |
| Net Profit Margin | -1,380.7% | -4,461.7% | -2,096.4% | -764.5% | - | - | -2,003.6% | -3,626.7% |
| Debt to Equity | 0.22x | 0.41x | 0.42x | 0.43x | 4.24x | - | 20.86x | 3.65x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Humacyte Inc dividends
Humacyte Inc has not paid dividends in the last 7 fiscal years.
Who owns Humacyte Inc
- Insiders 6.25%
- Institutions 26.53%
- Public & others 67.22%
- Shares outstanding 278M
- Free float 251M
Top funds holding HUMA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 7.72M | 2.78% | 0.00% | Sep 2026 |
| iShares Biotechnology ETF | 1.92M | 0.69% | -0.19% | Oct 2026 |
| Schwab US Small-Cap ETF™ | 1.35M | 0.49% | +0.24% | Oct 2026 |
| Fidelity Extended Market Index | 1.22M | 0.44% | +26.09% | Sep 2026 |
| Vanguard Health Care ETF | 768K | 0.28% | +0.11% | Sep 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 426K | 0.15% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 417K | 0.15% | +29.94% | Sep 2026 |
| Fidelity Series Total Market Index | 283K | 0.10% | 0.00% | Sep 2026 |
| AQR Delphi L/S Eq IAU1F | 185K | 0.07% | -50.00% | Mar 2026 |
| iShares Nasdaq US Biotech ETF USD Acc | 185K | 0.07% | +0.21% | Oct 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 156K | 0.06% | 0.00% | Oct 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 136K | 0.05% | 0.00% | Sep 2026 |
| Vanguard Balanced Index Inv | 132K | 0.05% | 0.00% | Sep 2026 |
| Gest Bout VIII Inver Value Global Fnd FI | 126K | 0.05% | 0.00% | Oct 2026 |
| Vanguard U.S. Eq Idx £ Acc | 105K | 0.04% | +110.13% | Sep 2026 |
| Fidelity ZERO Total Market Index | 97.5K | 0.04% | 0.00% | Sep 2026 |
| Fidelity ZERO Extended Market Index | 73.4K | 0.03% | -15.02% | Sep 2026 |
| Goldman Sachs Absolute Ret Trckr Instl | 55.8K | 0.02% | +283.61% | Jun 2026 |
| China Universal NASDAQ Bio-Tch ETF(QDII) | 35.3K | 0.01% | +15.79% | Jun 2026 |
| Solventis Hermes Multigestión R FI | 30.0K | 0.01% | 0.00% | Sep 2026 |
Top institutions holding HUMA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Capital Management, LLC | 10.1M | 3.64% | +41.20% | Jun 2026 |
| Antipodes Partners Limited | 10.1M | 3.64% | +76.52% | Jun 2026 |
| Alyeska Investment Group, L.P. | 6.02M | 2.17% | 0.00% | Jun 2026 |
| Davidson Kempner Capital Management LP | 5.00M | 1.80% | 0.00% | Jun 2026 |
| BlackRock Inc | 4.84M | 1.74% | -60.71% | Jun 2026 |
| Great Point Partners LLC | 3.75M | 1.35% | 0.00% | Jun 2026 |
| UBS Group AG | 2.84M | 1.02% | +2.21% | Jun 2026 |
| AQR Capital Management LLC | 2.60M | 0.93% | +34.94% | Jun 2026 |
| Geode Capital Management, LLC | 2.19M | 0.79% | -40.26% | Jun 2026 |
| Millennium Management LLC | 1.91M | 0.69% | +1,665.12% | Jun 2026 |
| Susquehanna International Group, LLP | 1.70M | 0.61% | +60.60% | Jun 2026 |
| Citadel Advisors Llc | 1.44M | 0.52% | 0.00% | Jun 2026 |
| Charles Schwab Investment Management Inc | 1.35M | 0.49% | +4.81% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 1.18M | 0.43% | +16.84% | Jun 2026 |
| HRT FINANCIAL LLC | 1.09M | 0.39% | 0.00% | Jun 2026 |
| LPL Financial Corp | 1.03M | 0.37% | +18.63% | Jun 2026 |
| GSA Capital Partners LLP | 1.01M | 0.36% | +302.52% | Jun 2026 |
| Private Advisor Group, LLC | 965K | 0.35% | +15.89% | Jun 2026 |
| State Street Corp | 843K | 0.30% | -72.32% | Jun 2026 |
| HBK INVESTMENTS L P | 790K | 0.28% | 0.00% | Jun 2026 |
Humacyte Inc company profile
- Company name
- Humacyte Inc
- Ticker
- HUMA.US
- Exchange
- USA Stocks
- Listed since
- Aug 26, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 184
- Fiscal year end
- December
- Address
- 2525 East North Carolina Highway 54, Durham, NC, United States, 27713
- Phone
- 919 313 9633
- Website
- humacyte.com
About Humacyte Inc
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.
Humacyte Inc management
9- Dr. Laura E. Niklason M.D., Ph.D.Founder, President, CEO & Director · born 1963
- Mr. Dale A. SanderCFO, Chief Corporate Development Officer & Treasurer · born 1960
- Dr. Shamik J. Parikh M.D.Chief Medical Officer · born 1973
- Ms. Sabrina Osborne GPHR, SPHRChief People Officer
- Ms. Lisa MolyneuxChief Strategy Officer
- Dr. Heather Connelly Ph.D.Chief Quality & Regulatory Officer
- Mr. Rick McElhenySenior Vice President of Business Development
- Mr. Jim MercadanteChief Commercial Officer
- Dr. Todd E. Rasmussen M.D.Chief Surgical Officer